Resolution Therapeutics Targets Liver Cirrhosis With Injectable mRNA Immune Cell Reprogramming
A new in vivo therapy aims to reprogram macrophages inside the body using mRNA and lipid nanoparticles, potentially replacing complex cell transplants.
Summary
Resolution Therapeutics has launched a new program to treat chronic inflammatory and fibrotic diseases, including end-stage liver cirrhosis, by reprogramming immune cells called macrophages directly inside the body. Using mRNA delivered via lipid nanoparticles — the same delivery technology behind COVID-19 vaccines — the approach aims to instruct macrophages to switch from causing inflammation to repairing damaged tissue. This in vivo method sidesteps the complex, personalized manufacturing required by their existing therapy, RTX001, which removes, reprograms, and reinfuses a patient's own cells. By testing multiple lipid nanoparticle formulations simultaneously through a deliberate fast-fail strategy, Resolution hopes to identify the most effective delivery systems quickly. Early results are expected later in 2025.
Detailed Summary
End-stage liver cirrhosis kills tens of thousands annually, and transplantation remains the only proven cure — yet donor organs are critically scarce. Resolution Therapeutics is pursuing a regenerative approach that could one day offer an alternative, targeting the immune cells already present in damaged tissue rather than relying on organ replacement.
The company's lead candidate, RTX001, is currently in the Phase 1/2 EMERALD trial for decompensated cirrhosis. It works by extracting a patient's macrophages, reprogramming them in a laboratory to promote tissue repair, and reinfusing them. While promising, this autologous process is resource-intensive and difficult to scale globally.
The new in vivo program takes a fundamentally different approach. Instead of removing cells, Resolution plans to inject mRNA packaged inside lipid nanoparticles directly into patients. The nanoparticles act as delivery vehicles, ferrying genetic instructions to macrophages inside the body and prompting them to switch into a tissue-repair mode without leaving the patient. If successful, this could eliminate multiple manufacturing steps and dramatically expand patient access.
To accelerate development, Resolution has signed Material Transfer Agreements with several independent lipid nanoparticle developers and plans to evaluate multiple delivery systems in parallel. This deliberate fast-fail strategy is designed to quickly eliminate underperforming formulations and concentrate resources on the most effective combinations. Alongside delivery optimization, researchers are refining mRNA payloads to ensure macrophages are activated for healing rather than inadvertently triggered toward more inflammation.
Interim data from the EMERALD trial and early in vivo program findings are both expected later this year. Caveats remain significant: this program is still preclinical, and translating mRNA-LNP technology from vaccines to targeted immune cell reprogramming in diseased tissue is a substantial biological and engineering challenge. Nevertheless, the dual-track strategy positions Resolution as a notable player in the emerging field of regenerative immunotherapy.
Key Findings
- Resolution Therapeutics launched an in vivo mRNA program to reprogram macrophages inside the body, targeting liver cirrhosis and fibrotic diseases.
- Lipid nanoparticles — proven in COVID-19 vaccines — will deliver mRNA instructions directly to macrophages, aiming to trigger tissue repair.
- The in vivo approach could eliminate complex cell manufacturing steps required by existing autologous therapy RTX001.
- A deliberate fast-fail strategy tests multiple lipid nanoparticle formulations simultaneously to rapidly identify the best delivery system.
- Interim data from the Phase 1/2 EMERALD trial of RTX001 in liver cirrhosis patients are expected later this year.
Methodology
This is a news report summarizing a company announcement from Resolution Therapeutics, a clinical-stage biotech. The article draws on a press release and CEO commentary rather than peer-reviewed data. Evidence basis is early-stage and corporate-sourced; independent clinical validation is pending.
Study Limitations
No peer-reviewed data are yet published for this in vivo program; findings are anticipated but unconfirmed. The article is based on a corporate announcement, introducing potential promotional bias. Readers should monitor the EMERALD trial registry and await independent interim data before drawing clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: